Stryker Launches Next Generation Trevo® ProVue™ Retrieval System
The World's First Fully Visible Stent Retriever Device to Treat Acute Ischemic
Stroke Expands Stryker's Commitment to Complete Stroke Care
KALAMAZOO, Mich., Nov. 8, 2012
KALAMAZOO, Mich., Nov. 8, 2012 /PRNewswire/ -- Stryker announced today the
global commercial launch of the new Trevo^® ProVue™ Retriever. The Trevo
ProVue Retriever is the first clot removal device fully visible during the
procedure for precise positioning within the clot and optimized clot retrieval
in patients experiencing acute ischemic stroke. Previous technology only
provided visibility to the edges of the device.
(Photo: http://photos.prnewswire.com/prnh/20121108/PH09237 )
"Trevo ProVue Retriever's full visibility provides a significant clinical
benefit," said Professor Liebig, M.D., Head of Neuroradiology, University
Hospital of Cologne in Cologne, Germany. "I am impressed with how full device
visibility provides more information during the procedure to quickly and
easily position the device and enables real-time feedback for a new level of
confidence to open blood vessels."
Oregon Health & Science University (OHSU) was the institution where the first
patient in the United States was treated using the Trevo^® ProVue™ Retriever.
"It is of great benefit to be able to see how a device interacts with the clot
within the vessel, and may be able to demonstrate an underlying stenosis, as
it did in the first patient we treated with the device," said Gary Nesbit,
M.D., Professor of Neuroradiology, Neurology, Neurosurgery, and the Dotter
Interventional Institute at OHSU. "This gives me better information for
clinical decisions and potentially increases the chance for better outcomes
for my patients."
"Trevo ProVue represents our dedication to providing patients and physicians
with the most advanced tools available to treat acute ischemic stroke," said
Mark Paul, President of Stryker's Neurovascular division. "Trevo ProVue sets a
new standard in stent retriever technology. It's the first fully visible
device allowing physicians to visualize placement, clot interaction and
retrieval – that can make a big difference in patient treatment."
The Trevo^® ProVue™ Retriever is supported by robust clinical evidence from
the Trevo^® family of Retrievers in the TREVO and TREVO 2 clinical trials,
which demonstrated high revascularization and improved clinical outcomes
compared to the first generation Merci Retriever^®. The device has been
granted 510(k) market clearance by the U.S. Food and Drug Administration and
is also available in international markets where it has been cleared for sale.
View an animation of the Trevo^® ProVue™ Retriever on Stryker's YouTube
Stryker is one of the world's leading medical technology companies and is
dedicated to helping healthcare professionals perform their jobs more
efficiently while enhancing patient care. The Company offers a diverse array
of innovative medical technologies, including reconstructive, medical and
surgical, and neurotechnology and spine products to help people lead more
active and more satisfying lives. For more information about Stryker, please
Press spacebar to pause and continue. Press esc to stop.